Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
NCT01866293
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
11
Enrollment
OTHER
Sponsor class
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
DRUG:
Cabozantinib (XL184)
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
[object Object]